Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer

被引：9

作者：

Liu, Yi-Fu ^{[1
]}

Fu, Sheng-Qiang ^{[1
]}

Yan, Yu-Chang ^{[1
]}

Gong, Bin-Bin ^{[1
]}

Xie, Wen-Jie ^{[1
]}

Yang, Xiao-Rong ^{[1
]}

Sun, Ting ^{[1
]}

Ma, Ming ^{[1
]}

机构：

[1] Nanchang Univ, Affiliated Hosp 1, Dept Urol, Nanchang 330000, Jiangxi, Peoples R China

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2021年 / 15卷

关键词：

gonadotropin-releasing hormone; prostate cancer; degarelix; relugolix; ANDROGEN-DEPRIVATION THERAPY; ANTIANDROGEN FLARE PROTECTION; URINARY-TRACT SYMPTOMS; III EXTENSION TRIAL; OF-LIFE IMPROVEMENT; OPEN-LABEL; GNRH ANTAGONIST; PHASE-II; JAPANESE PATIENTS; 1-ARM CROSSOVER;

D O I：

10.2147/DDDT.S291369

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Gonadotropin-releasing hormone (GnRH) receptor agonists are still the most commonly used androgen deprivation treatment (ADT) drugs for prostate cancer in clinical practice. Currently, the GnRH receptor antagonists used for endocrine therapy for prostate cancer primarily include degarelix and relugolix (TAK-385). The former is administered by subcutaneous injection, while the latter is an oral drug. Compared to GnRH agonists, GnRH antagonists reduce serum testosterone levels more rapidly without an initial testosterone surge or subsequent microsurges. This review focuses on the mechanism of action of GnRH antagonists and agonists, the developmental history of GnRH antagonists, and emerging data from clinical studies of the two antagonists used as endocrine therapy for prostate cancer.

引用

页码：639 / 649

页数：11

共 50 条

[1] Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer
Moussa, Mohamad
Papatsoris, Athanasios
Dellis, Athanasios
Abou Chakra, Mohamed
Fragkoulis, Charalampos
EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (17) : 2373 - 2381
[2] The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer
Cirne, Filipe
Aghel, Nazanin
Petropoulos, Jo-Anne
Klotz, Laurence
Lenihan, Daniel J.
Saad, Fred
Pinthus, Jehonathan
Leong, Darryl P.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (03) : 253 - 262
[3] Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer
George, Daniel J.
Dearnaley, David P.
FUTURE ONCOLOGY, 2021, 17 (33) : 4431 - 4446
[4] Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer
Anderson, John
FUTURE ONCOLOGY, 2009, 5 (04) : 433 - 443
[5] Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer
Van Poppel, Hendrik
Abrahamsson, Per-Anders
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (10) : 830 - 837
[6] Gonadotropin-releasing hormone: An update review of the antagonists versus agonists
Van Poppel, Hein
Klotz, Laurence
INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (07) : 594 - 601
[7] Degarelix: A Gonadotropin-Releasing Hormone Antagonist for the Management of Prostate Cancer
Steinberg, Michael
CLINICAL THERAPEUTICS, 2009, 31 : 2312 - 2331
[8] Gonadotropin-releasing hormone antagonist: A real advantage?
Kimura, Takahiro
Sasaki, Hiroshi
Akazawa, Kouhei
Egawa, Shin
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (07) : 322 - 328
[9] Relugolix: A Novel Gonadotropin-Releasing Hormone Antagonist for Prostate Cancer
Babu, Merin
Pavithran, Keechilat
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2021, 12 (01) : 26 - 28
[10] Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study
Chen, Dong-Yi
Su, Po-Jung
See, Lai-Chu
Liu, Jia-Rou
Chuang, Cheng-Keng
Pang, See-Tong
Tseng, Chi-Nan
Chen, Shao-Wei
Hsieh, I-Chang
Chu, Pao-Hsien
Lin, Yung-Chang
Hsu, Cheng-Lung
Chang, John Wen-Cheng
Lin, Miao-Sui
Pang, Jong-Hwei S.
Hsieh, Ming-Jer
Huang, Wen-Kuan
PROSTATE, 2021, 81 (12) : 902 - 912

← 1 2 3 4 5 →